Page 2 - Will Chou News Today

Share this article Share this article NEW YORK and BASEL, Switzerland, May 4, 2021 /PRNewswire/ -- Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, announced it has added eleven scientists to its manufacturing, preclinical and clinical teams, a major milestone in the companys strategy to build a beginning-to-end internal-external supply model led by its pioneering cell and gene therapy expertise. Additional expansion in clinical, technica...

Press release content from PR Newswire. The AP news staff was not involved in its creation. Aruvant Announces Oral Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting April 27, 2021 GMT (PRNewsfoto/Aruvant Sciences) NEW YORK and BASEL, Switzerland, April 27, 2021 /PRNewswire/ -- Aruvant Sciences (“Aruvant”), a private company focused on developing gene therapies for rare diseases, today announced that data on ARU-1801, a potentially curative gene therapy...

Share this article Share this article NEW YORK and BASEL, Switzerland, April 23, 2021 /PRNewswire/ -- Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, today announced the appointment of Meghan Kelton, executive director, human resources (HR), and E. Blair Clark-Schoeb, senior vice president, communications, to the Aruvant leadership team.  "Ms. Keltons HR experience in gene therapy and Ms. Clark-Schoebs public company and rare disease co...

Press release content from PR Newswire. The AP news staff was not involved in its creation. Aruvant to Participate in Numerous Scientific and Investor Conferences in February and March February 11, 2021 GMT (PRNewsfoto/Aruvant Sciences) NEW YORK and BASEL, Switzerland, Feb. 11, 2021 /PRNewswire/ -- Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene therapies for the treatment of rare diseases, today announced management participatio...

Share this article Share this article NEW YORK, Feb. 3, 2021 /PRNewswire/ -- Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, today announced that the European Medicines Agency (EMA) granted Priority Medicines (PRIME) designation to ARU-1801, a one-time investigational gene therapy for sickle cell disease (SCD).  "PRIME designation from EMA highlights the importance of ARU-1801, administered with only reduced intensity conditioning, for the treat...